Show simple item record

dc.contributor.authorSchonhoff, Christopher M.
dc.contributor.authorDaou, Marie-Claire
dc.contributor.authorJones, Stephen N.
dc.contributor.authorSchiffer, Celia A.
dc.contributor.authorRoss, Alonzo H.
dc.date2022-08-11T08:08:48.000
dc.date.accessioned2022-08-23T16:08:43Z
dc.date.available2022-08-23T16:08:43Z
dc.date.issued2002-11-13
dc.date.submitted2008-12-10
dc.identifier.citation<p>Biochemistry. 2002 Nov 19;41(46):13570-4.</p>
dc.identifier.issn0006-2960 (Print)
dc.identifier.doi10.1021/bi026262q
dc.identifier.pmid12427017
dc.identifier.urihttp://hdl.handle.net/20.500.14038/32515
dc.description.abstractIt has become increasingly evident that nitric oxide exerts its effects, in part, by S-nitrosylation of cysteine residues. We tested in vitro whether nitric oxide may indirectly control p53 by S-nitrosylation and inactivation of the p53 negative regulator, Hdm2. Treatment of Hdm2 with a nitric oxide donor inhibits Hdm2-p53 binding, a critical step in Hdm2 regulation of p53. The presence of excess amounts of cysteine or dithiothreitol blocks this inhibition of binding. Moreover, nitric oxide inhibition of Hdm2-p53 binding was found to be reversible. Sulfhydryl sensitivity and reversibility are consistent with nitrosylation. Finally, we have identified a critical cysteine residue that nitric oxide modifies to disrupt Hdm2-p53 binding. This cysteine is proximal to the Hdm2-p53 binding interface and is conserved across species from zebrafish to humans. Mutation of this residue from a cysteine to an alanine does not interfere with binding but rather eliminates the sensitivity of Hdm2 to nitric oxide inactivation.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=12427017&dopt=Abstract">Link to Article in PubMed</a></p>
dc.relation.urlhttps://doi.org/10.1021/bi026262q
dc.subjectAmino Acid Sequence; Binding Sites; Cysteine; Dithiothreitol; Enzyme-Linked Immunosorbent Assay; Glutathione; Glutathione Transferase; Humans; Molecular Sequence Data; Mutagenesis, Site-Directed; Mutation; Neoplasm Proteins; *Nuclear Proteins; Protein Binding; Protein Conformation; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Recombinant Fusion Proteins; Sequence Homology, Amino Acid; Triazenes; Tumor Suppressor Protein p53
dc.subjectLife Sciences
dc.subjectMedicine and Health Sciences
dc.titleNitric oxide-mediated inhibition of Hdm2-p53 binding
dc.typeJournal Article
dc.source.journaltitleBiochemistry
dc.source.volume41
dc.source.issue46
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/gsbs_sp/1081
dc.identifier.contextkey679619
html.description.abstract<p>It has become increasingly evident that nitric oxide exerts its effects, in part, by S-nitrosylation of cysteine residues. We tested in vitro whether nitric oxide may indirectly control p53 by S-nitrosylation and inactivation of the p53 negative regulator, Hdm2. Treatment of Hdm2 with a nitric oxide donor inhibits Hdm2-p53 binding, a critical step in Hdm2 regulation of p53. The presence of excess amounts of cysteine or dithiothreitol blocks this inhibition of binding. Moreover, nitric oxide inhibition of Hdm2-p53 binding was found to be reversible. Sulfhydryl sensitivity and reversibility are consistent with nitrosylation. Finally, we have identified a critical cysteine residue that nitric oxide modifies to disrupt Hdm2-p53 binding. This cysteine is proximal to the Hdm2-p53 binding interface and is conserved across species from zebrafish to humans. Mutation of this residue from a cysteine to an alanine does not interfere with binding but rather eliminates the sensitivity of Hdm2 to nitric oxide inactivation.</p>
dc.identifier.submissionpathgsbs_sp/1081
dc.contributor.departmentDepartment of Cell Biology
dc.contributor.departmentDepartment of Biochemistry and Molecular Pharmacology
dc.contributor.departmentGraduate School of Biomedical Sciences
dc.source.pages13570-4


This item appears in the following Collection(s)

Show simple item record